Therefore, detecting somatic alterations is of particular importance in the search for alternative ovarian cancer therapies because recent studies have shown that inhibitors of poly(ADP-ribose) polymerase (PARP) are potential targeted therapies for ovarian cancers with loss of BRCA1 and/or BRCA2 function [11]. The gene discussed is BRCA1; the disease is ovarian cancer.